Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Kistos on track to hit guidance, but H1 profits sink

(Sharecast News) - Energy company Kistos said it remains firmly on track to hit its full-year production guidance after a period of "significant and transformational investment" in the first half, though results were significantly lower than last year. The North Sea-focused company reported an average production rate of 6,200 barrels of oil equivalents (boe) per day in the six months to 30 June, down 26% on the year before, with a slight improvement in output from Norway outweighed by heavy falls in the UK and Netherlands.

Revenues fell 22% to $87.9m, as an 18% slump in the average realised oil price to $67 a barrel was only partially offset by a 43% jump in the average realised gas price to $77/boe.

Adjusted EBITDA for the period totalled $23.7m, down 51% from last year, as unit opex increased to $42/boe from $29/boe due to lower production in the Netherlands and UK.

Nevertheless, the company remains upbeat: "The group is on track to meet our full-year production guidance of 8,000-9,000 boepd whilst upholding strong operational performance and unlocking the full potential of our existing asset base to deliver long-term value for shareholders," said executive chair Andrew Austin.

The stock, which has gained nearly 50% so far this year, was up 0.6% at 164.92p by 1234 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.